Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07474792 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
A Phase 2 study, sponsored by Oruka Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT07474792: Recruiting Phase 2 study, sponsored by Oruka Therapeutics.
NCT07474792 is a Phase 2 study that is actively recruiting participants, run by Oruka Therapeutics. The registered enrollment target is 160 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07474792, a Phase 2 study, is actively recruiting participants, sponsored by Oruka Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.
Primary Outcome
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).
Interventions
- OTHER Placebo
- DRUG ORKA-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-03-19 |
| Est. Completion | 2029-04 |
| Phase | Phase 2 |
What NCT07474792 shows while recruiting
NCT07474792 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07474792 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07474792 about?
NCT07474792 is a clinical study titled "Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis". This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT07474792?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2026-03-19. Estimated completion is 2029-04.
What interventions are being tested in trial NCT07474792?
The interventions under investigation include: Placebo (OTHER), ORKA-002 (DRUG).
Who is sponsoring clinical trial NCT07474792?
This trial is sponsored by Oruka Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07474792's enrollment target sits among peer trials
160 422nd of 2000 higher than 1,559 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI